IL2 and nonpapillary renal cell carcinoma: Presently, surgery is the main treatment for ccRCC, whereas adjuvant interleukin 2 (IL-2) therapy, interferon (IFN) therapy, chemotherapy, radiotherapy, and hormonal therapy for ccRCC at high recurrence risk do not prolong overall patient survival [4].